Cingulate (CING) Cash from Operations (2021 - 2025)
Cingulate's (CING) quarterly Cash from Operations came in at 3597289.0 in Q4 2025, up 11.82% YoY from 3217006.81 in Q4 2024, and up 21.94% on a QoQ basis from 4608282.0 in Q1 2025.
Cingulate (CING) Cash from Operations (2021 - 2025) Analysis & Trends
Cingulate (CING) has 5 years of Cash from Operations data on file, last reported at 3597289.0 in Q4 2025.
- Quarterly Cash from Operations rose 11.82% year-over-year to 3597289.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 16168558.0 (up 12.37% YoY) and the FY2025 annual result came in at 17245182.0, up 6.54% from the prior year.
- Cash from Operations climbed to 3597289.0 in Q4 2025, from 4608282.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1550713.0 in Q2 2021 to a low of 8746360.0 in Q1 2024.
- A 5-year average of 3778171.17 and a median of 3873970.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 184.53% — and 2024, when it soared 62.16%.
- Tracing CING's Cash from Operations over 5 years: stood at 4622763.0 in 2021, then grew by 9.0% to 4206494.0 in 2022, then surged by 39.09% to 2562371.0 in 2023, then tumbled by 59.21% to 4079530.0 in 2024, then rose by 11.82% to 3597289.0 in 2025.
- The last three Cash from Operations figures came in at 3597289.0 (Q4 2025), 4608282.0 (Q1 2025), and 4079530.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.60 Mn |
| Dec 31, 2025 | -3.60 Mn |
| Mar 31, 2025 | -4.61 Mn |
| Mar 31, 2025 | -4.61 Mn |
| Dec 31, 2024 | -4.08 Mn |
| Dec 31, 2024 | -4.08 Mn |
| Sep 30, 2024 | -3.88 Mn |
| Sep 30, 2024 | -3.88 Mn |
| Jun 30, 2024 | -1.74 Mn |
| Jun 30, 2024 | -1.74 Mn |
| Mar 31, 2024 | -8.75 Mn |
| Mar 31, 2024 | -8.75 Mn |
| Dec 31, 2023 | -2.56 Mn |
| Dec 31, 2023 | -2.56 Mn |
| Sep 30, 2023 | -4.29 Mn |
| Sep 30, 2023 | -4.29 Mn |
| Jun 30, 2023 | -4.60 Mn |
| Jun 30, 2023 | -4.60 Mn |
| Mar 31, 2023 | -3.58 Mn |
| Mar 31, 2023 | -3.58 Mn |